Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
2006 1
2014 1
2015 1
2017 1
2022 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean yoo hee (229 results)?
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
Khanna S, Assi M, Lee C, Yoho D, Louie T, Knapple W, Aguilar H, Garcia-Diaz J, Wang GP, Berry SM, Marion J, Su X, Braun T, Bancke L, Feuerstadt P. Khanna S, et al. Drugs. 2022 Oct;82(15):1527-1538. doi: 10.1007/s40265-022-01797-x. Epub 2022 Oct 26. Drugs. 2022. PMID: 36287379 Free PMC article. Clinical Trial.
Artificial intelligence in research.
Musib M, Wang F, Tarselli MA, Yoho R, Yu KH, Andrés RM, Greenwald NF, Pan X, Lee CH, Zhang J, Dutton-Regester K, Johnston JW, Sharafeldin IM. Musib M, et al. Science. 2017 Jul 7;357(6346):28-30. doi: 10.1126/science.357.6346.28. Science. 2017. PMID: 28684488 No abstract available.
Correction to: Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
Khanna S, Assi M, Lee C, Yoho D, Louie T, Knapple W, Aguilar H, Garcia-Diaz J, Wang GP, Berry SM, Marion J, Su X, Braun T, Bancke L, Feuerstadt P. Khanna S, et al. Drugs. 2022 Oct;82(15):1539. doi: 10.1007/s40265-022-01805-0. Drugs. 2022. PMID: 36342618 Free PMC article. No abstract available.
Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial.
Orenstein R, Dubberke ER, Khanna S, Lee CH, Yoho D, Johnson S, Hecht G, DuPont HL, Gerding DN, Blount KF, Mische S, Harvey A. Orenstein R, et al. BMC Infect Dis. 2022 Mar 12;22(1):245. doi: 10.1186/s12879-022-07256-y. BMC Infect Dis. 2022. PMID: 35279084 Free PMC article. Clinical Trial.
Study of ten anatomical variants of the foot and ankle.
Chaney DM, Lee MS, Khan MA, Krueger WA, Mandracchia VJ, Yoho RM. Chaney DM, et al. J Am Podiatr Med Assoc. 1996 Nov;86(11):532-7. doi: 10.7547/87507315-86-11-532. J Am Podiatr Med Assoc. 1996. PMID: 8961655
Randomized controlled study of excimer laser atherectomy for treatment of femoropopliteal in-stent restenosis: initial results from the EXCITE ISR trial (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis).
Dippel EJ, Makam P, Kovach R, George JC, Patlola R, Metzger DC, Mena-Hurtado C, Beasley R, Soukas P, Colon-Hernandez PJ, Stark MA, Walker C; EXCITE ISR Investigators. Dippel EJ, et al. JACC Cardiovasc Interv. 2015 Jan;8(1 Pt A):92-101. doi: 10.1016/j.jcin.2014.09.009. Epub 2014 Dec 10. JACC Cardiovasc Interv. 2015. PMID: 25499305 Free article. Clinical Trial.